Beta Drugs Ltd. · NSE:BETA
Beta Drugs — FY2026 Earnings Presentation
23 slides from Beta Drugs's earnings presentation, May 15, 2026
Slide 1: FY26 – Annual Result
FY26 – Annual Result May 2026
Slide 2: Roadmap for strategic transformation
Roadmap for strategic transformation
Slide 3: Beta Vision 2030: Strategic transformation creating enduring value
Beta Vision 2030: Strategic transformation creating enduring value FY21 FY26 FY30 Other Other Other 6% 7% CMO 6% Branded 13% 28% Branded 36% Branded CMO 51% CMO 39% 50% Export Export 16% 30% Export 18% Key Strategic Priorities Creating a strong branded franchise- to be among the top 5 & the fastest
Slide 4: Disciplined capital allocation focused on sustainable value creation
Disciplined capital allocation focused on sustainable value creation 4 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 5: FY26: Financial Performance
FY26: Financial Performance 5 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 6: FY26 Performance: Strengthening our pillars of growth
FY26 Performance: Strengthening our pillars of growth FY26 Revenue Key Highlights for FY26 Deeper penetration in key accounts/hospitals Healthy pipeline that continues to drive sales Branded Segment 140 Cr Building deeper & long-term relationship with customer Derma clocked the sales of 16.6 Crs, gr
Slide 7: FY26: Segment Performance Overview
FY26: Segment Performance Overview 7 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 8: Branded Segment: Strong Execution drives sustained growth
Branded Segment: Strong Execution drives sustained growth Consistent growth in Branded Oncology Segment Product pipeline and Marquee Customers 123 NDDS 33 ● Megestrol acetate O/S ● Methotrexate O/S FY21 FY26 ● Imatinib Suspension ● 5 products under development Execution excellence Track record of sc
Slide 9: Meaningful presence across all key segments of Oncology treatment protocols
Meaningful presence across all key segments of Oncology treatment protocols Our coverage in different segments of Oncology - Present in Oncology & Cosmeceutical therapeutic areas - 135+ products in Oncology - Products available in more 85% of corporate & Govt hospitals 84% market 62% market 26% mark
Slide 10: R&D led innovation: enabling strong clinical differentiation
R&D led innovation: enabling strong clinical differentiation Demonstrated consistency in introducing innovative products Successful product launches (FY26) 60 ml 15 13 12 FY20 - FY 21 FY22 - FY 23 FY24 - FY 26 Well-established track record of NDDS product introductions Product pipeline – spread acro
Slide 11: Dermatology: Enhancing portfolio with differentiated portfolio additions
Dermatology: Enhancing portfolio with differentiated portfolio additions Agreement with the European Exclusive agreement with company for the “First to Frezyderm to launch their launch” product - premium cosmeceutics: Mesotherapy in Indian anti ageing, Depigmenting Cosmeceutical market etc. Tracking
Slide 12: Exports: Identified core geographies to power long term growth
Exports: Identified core geographies to power long term growth Core geographies: Large addressable markets with attractive underlying growth Exports to be a cornerstone of Beta’s transformative journey Geography Est. Mkt Size (USD Bn) Est. Mkt Growth Export, 18% 2.5 10% FY26 1.4 10%-12% Africa 4.0 8
Slide 13: Exports: Establishing the strong foundation in the core geographies
Exports: Establishing the strong foundation in the core geographies Core geographies – driving export sales Cumulative dossier registrations across core geographies MENA 7% APAC 105 32% 90 LATAM 59 No of 42% AFRICA registrations till date 26 19% LatAm APAC MENA AFRICA Registrations momentum continue
Slide 14: CMO: Most trusted CMO partner in India catering to marquee customers
CMO: Most trusted CMO partner in India catering to marquee customers • Clocked ~INR 150 Crs. turnover • Suppliers to most leading oncology formulation companies Largest Oncology • 95%+ repeat business from key customers CMO We value our Trusted CDMO partners Partners Growth Strategy • Focus on high
Slide 15: API: Backward integration provides significant lever for future margin expansion
API: Backward integration provides significant lever for future margin expansion Wide portfolio of API 80% API facility with a world- related to Oncology of API for formulations class microbial lab with drugs manufactured in-house the latest equipment API business provides competitive advantage FY26
Slide 16: NIVIAN: Beta’s foray into the IVF segment
NIVIAN: Beta’s foray into the IVF segment 16 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 17: Nivian: Beta’s foray in the fast-growing IVF market
Nivian: Beta’s foray in the fast-growing IVF market ------------------------------------------------------------ India IVF market estimate (INR Crs.) Nivian at a glance 3,800 2,000 31 15 11 1,500+ Products States & UTs 3rd Party Fertility clinics Manufacturers FY26 FY30 IVF market to outpace the Ind
Slide 18: Nivian: A scaled-up, dynamic company focused on IVF segment
Nivian: A scaled-up, dynamic company focused on IVF segment ------------------------------------------------------------ Nivian: leading high growth IVF pharma company Formidable brand franchise (FY26) 50 25 Top 5 Brands - 69% 43 35 21 15 - FY23 FY24 FY25 FY26 Spread of Sales & marketing team across
Slide 19: FY26: Balance Sheet
FY26: Balance Sheet 19 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 20: Balance Sheet - Summary
Balance Sheet - Summary FY’24 FY’25 FY’26 (Rs Cr) (Rs Cr) (Rs Cr) Share capital 9.61 10.09 10.13 Reserves 147.5 187.00 234.63 Borrowing (Long term & 11.00 136.38 147.80 short term) Other liabilities 85.98 102.75 103.22 Total liabilities 254.09 436.23 495.79 Fixed asset 64.59 88.93 125.26 (Net of dep
Slide 21: Key Ratios
Key Ratios -------------------------------------- Debt to Equity Ratio % Gross Margin 0.74 55.52% 0.63 52.7% 49.5% 0.10 FY'24 FY'25 FY'26 FY'24 FY'25 FY'26 ------------------------------------------------------------------------------------------------------------------------------------------------
Slide 22: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 23: THANK YOU
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com 23 Privileged & Confidential, © 2026, All Rights Reserved.